Does adjuvant ipilimumab have little adverse effect on quality of life?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2017.60.pdf
Reference7 articles.
1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
2. van Akkooi, A. C., Atkins, M. B., Agarwala, S. S. & Lorigan, P. Surgical management and adjuvant therapy for high-risk and metastatic melanoma. Am. Soc. Clin. Oncol. Educ. Book 35, e505–e514 (2016).
3. Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
4. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).
5. Coens, C. et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 18, 393–403 (2017).
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Patient engagement in melanoma research: from bench to bedside;Future Oncology;2021-10
2. Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review;Journal of Patient-Reported Outcomes;2020-07-16
3. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016);Value in Health;2019-02
4. Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy;Clinical and Translational Oncology;2018-11-21
5. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report;Cancer Immunology, Immunotherapy;2017-12-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3